MetricSide LogoMetricSide
Learn
  1. Home
  2. Companies
  3. Healthcare
  4. ELV
OverviewMetricsPricesRevenue & ProfitAssets & LiabilitiesCash FlowMarginsPrice RatiosOthers
MetricSide

Standardized stock fundamentals and valuation metrics. Analyze revenue, EBITDA, free cash flow, and more with interactive charts.

Stock Sectors

  • Technology
  • Healthcare
  • Financials
  • Consumer
  • Industrials
  • Energy
  • Real Estate
  • Materials

Legal & Contact

  • Terms of Service
  • Privacy Policy
  • Contact Us
Not Financial Advice: MetricSide is a data aggregation and visualization tool. Nothing on this website constitutes investment advice, a recommendation, or a solicitation to buy or sell any security. All data is provided for informational and educational purposes only. Past performance is not indicative of future results. Always consult a qualified financial professional before making investment decisions. Data accuracy is not guaranteed — verify critical information against official sources.

© 2026 MetricSide. All rights reserved.

Elevance Health (ELV) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Elevance Health
NYSE•Healthcare•Healthcare Plans
$414.26+1.70(<0.01%)After hours
Market Cap
$88.22B
P/E
17.8x
P/S
0.4x
P/B
2.0x

Elevance Health, Inc., together with its subsidiaries, operates as a health benefits company in the United States. The company operates in four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to individual, employer group risk-based and fee-based, BlueCard, Medicare, Medicaid, and FEP members; health products; a broad array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, and supplemental health insurance benefits. The company also operates in the pharmacy services business; and markets and offers pharmacy services, including home delivery and specialty pharmacies, claims adjudication, formulary management, pharmacy networks, rebate administration, a prescription drug database, and member services, as well as infusion services and injectable therapies through ambulatory infusion centers. In addition, it provides healthcare related services and capabilities, including specialty care enablement and utilization management support for specialized clinical domains; behavioral health and comprehensive care management services; palliative care services and management; virtual care; and payment integrity, subrogation, clinical data exchange through its HealthOS platform, research and data, reporting and clinical analytics, information technology, and business process support services, as well as manages home health, post-acute institutional management, and durable medical equipment costs; and supports plans in managing home and community-based services. The company provides its services under the Anthem Blue Cross and Blue Shield, Wellpoint, and Carelon brands. The company was formerly known as Anthem, Inc. and changed its name to Elevance Health, Inc. in June 2022. Elevance Health, Inc. was incorporated in 2001 and is based in Indianapolis, Indiana.

C

How this company scores

AverageMetricSide Score: 58/100

Strongest: Cash & Earnings Quality (22/25); weakest: Profitability (8/25).

Profitability8/25
Growth14/25
Balance Sheet & Red Flags14/25
Cash & Earnings Quality22/25
Strengths
Rising free cash flowNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 17.8x5y range 11.9x – 22.0x
P/E 17.8x · near its 20-quarter median

Currently near its 20-quarter median.

P/S · 0.4x5y range 0.3x – 0.8x
P/S 0.4x · near its 20-quarter median

Currently near its 20-quarter median.

P/B · 2.0x5y range 1.4x – 3.4x

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

Operating margins dropped 32.2% over recent quarters — a sharp decline suggesting serious cost or pricing challenges.

Earnings Quality

Watch

FCF/Net Income has dropped below 0.7x in 3 quarters — monitor for earnings quality deterioration.

Price & Volume
Market Cap $88.22B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue
$201.11B
6Q
Q. Revenue
$50.47B
2Q
TTM EBITDA
$5.45B
5Q
TTM Op. Income
$5.45B
5Q
Q. Op. Income
$1.76B
27%
TTM Net Income
$4.96B
2Q
Q. Net Income
$1.46B
16%
EPS
$6.74
13%
Shares Out.
$217.00M
7Q
$201.11B in TTM revenue grew 6.3% YoY, reaching $50.47B last quarter. TTM EBITDA of $5.45B and TTM operating income of $5.45B show growth is flowing through to the bottom line. TTM net income of $4.96B means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin
26.6%
1%
EBITDA Margin
3.5%
28%
Op. Margin
3.5%
28%
Net Margin
2.9%
17%
Op. margin of 3.5% is down 1.4% YoY — costs are rising relative to revenue. Net margin at 2.9% and gross margin of 26.6% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 28% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio
17.8x
9%
P/S Ratio
0.4x
5%
P/B Ratio
2.0x
2%
At 17.8x P/E, the stock trades within typical market levels. P/S of 0.4x and P/B of 2.0x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 9% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets
$126.44B
2Q
Cash
$10.23B
5Q
Long-Term Debt
$30.67B
3Q
Book Value
$44.88B
2Q
D/E Ratio
0.7
3Q
Debt/EBITDA
17.4
50%
With $126.44B in assets and $30.67B in long-term debt, D/E is 0.7and book value is $44.88B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has fallen for 3 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow
$1.91B
7%
TTM Free Cash Flow
$6.29B
18%
FCF Margin
3.1%
11%
FCF / Net Income
1.3
2Q
TTM FCF of $6.29B on $1.91B in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 18% — a weakening trend.

Related Stocks in Healthcare

View Sector
LLY$938.28B
Lilly (Eli)
Drug Manufacturers - General
JNJ$586.47B
Johnson & Johnson
Drug Manufacturers - General
ABBV$411.57B
AbbVie
Drug Manufacturers - General
MRK$303.29B
Merck & Co.
Drug Manufacturers - General
UNH$249.74B
UnitedHealth Group
Healthcare Plans
TMO$203.77B
Thermo Fisher Scientific
Diagnostics & Research
AMGN$201.34B
Amgen
Drug Manufacturers - General
GILD$191.61B
Gilead Sciences
Drug Manufacturers - General
P/B 2.0x
· below its 20-quarter median

Currently below its 20-quarter median.